Search results for:

epiRUBicin

epiRUBicin
  • Restricted Medications IV Chemotherapy
Brand names: Ellence
Form Strength
POWDER FOR INJECTION, INTRAVENOUS 50 mg
SOLUTION, INTRAVENOUS 2 mg/mL
Display Antineoplastic Agents Class: 100000
High Alert Drug : Policy
Medication comments:

Chemo rounding - may round chemo DOWN to nearest vial if dose within ≤ 5% of ordered dose.
Chemo doses will not be rounded up. (Approved 12/18)
High Alert Drug: Chemotherapeutic Agents - Parenteral
 • Stored separately in pharmacy.
 • Pharmacist reviews literature in order to to verify calculations and dose prescribed.
 • Two pharmacists independently verify preparation.
 • No telephone orders. Pre-printed order sheet available.
 • Chemo is administered by specially trained RNs.
 • 2 RNs independently verify pump settings and drug on continuous infusions prior to administration.
 • IV sites are assessed every 2 hours.
 • Drugs are transported in plastic bags/designated transport containers labeled with sticker indicating CHEMOTHERAPY DRUG.
Per policy, these medications require cardiac and/or special monitoring.
(KEY: "Y" = may be given as described on chart. "N" = may NOT be given except in Rapid Response/Code Blue situations or as otherwise described in Exceptions section of Policy.
generic (Brand) / Notes CCU, OR, PACU, CCL, ED PCU 2N (Tele) 1N (Tele), 3N (Tele) Med/Surg (1N w/o Tele, 3N w/o Tele, 4N, 5N) BirthPlace SNF ICS OPS
cytotoxic agents (chemotherapy)
IV Push, IV Infusion (chemotherapy) Key: certified RN and 1N designated staff only		 Y
(CCU only)		 N N Y
(1N only)		 Y
(1N only)		 N N Y N
Per policy, these hazardous drugs have special waste requirements. 
Generic (Brand) Waste Requirements
epiRUBicin (Ellence) If > 3% by weight of drug remains ⇒  BLACK BUCKET 
Trace amounts/uncontaminated PPE ⇒  YELLOW BUCKET 
USP <800> Hazardous Drugs 
Per Policy, these drugs have special handling requirements (any drug with an "AOR" is exempt from these requirements under normal circumstances).
generic (Brand) Route Relative Risk Level AOR? NIOSH 2024 Table MSHI?↑ Warnings
 epiRUBicin (Ellence) IV High N/A 1↑ Yes  
NIOSH Supplemental information (2016): N/A FDA Pregancy Category D: There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks;
Adult Extravasation Management
epiRUBicin (Ellence)
Agent type: Chemotherapeutic
Vesicant/Irritant: Vesicant
Local Care: Cold compress
Antidote: Dexrazoxane or topical DMSO. Do not use in combination with each other due to decreased efficacy of dexrazoxane.
Antidote link(s):
Comments: • Do not apply heat, it may worsen injury
• Protect site from heat and sunligh
• Corticosteroids worsen toxicity
Last updated: Jun. 18, 2025
UpToDate Lexidrug

Pharmacy Contact Info:

Main Inpatient Pharmacy: ext 4599, 3503
Fax: 704-878-7283

Director of Pharmacy - Randi Raynor, PharmD: ext 4501
Clinical Coordinator - Laura Rollings, PharmD: ext 4597
Pharmacy Informaticist - Stephen Pringle, PharmD: ext 7645
Pharmacy Technician Supervisor - Amy Wingler, CPhT: ext 7385
Pharmacy Automation Coordinator (Omnicell) - Melissa Fulford, CPhT: ext 3556



This site is intended for the staff of Iredell Health System. While others may view accessible pages, Iredell Health System makes no warranty, express or implied, as to the use of this information outside of Iredell Health System. The content of this policy and procedure document serves as guidance to the delivery of quality patient care. Care providers are expected to exercise critical thinking and situational awareness skills, and in specific situations to take such action as is necessary for the delivery of quality patient care.
Copyright © 2025 Rpharmy, LLC ­ All Rights Reserved